Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • IDH1-mutated AML
Ivosidenib Plus Azacitidine Significantly Improves Survival in IDH1-Mutated AML: Long-Term Results from the AGILE Study
Posted inClinical Updates Wellness & Lifestyle

Ivosidenib Plus Azacitidine Significantly Improves Survival in IDH1-Mutated AML: Long-Term Results from the AGILE Study

Posted by By MedXY 07/31/2025
The AGILE trial shows ivosidenib plus azacitidine more than triples median overall survival in newly diagnosed IDH1-mutated AML patients ineligible for intensive chemotherapy, with improved hematologic recovery and safety.
Read More
  • How Should Diabetic Patients Consume Fruits?
  • 30 Practical Tips for Effective and Healthy Weight Loss
  • Can Merely Seeing Infection Activate Real Immunity? The Neuroscience of Virtual Pathogens and Immunological Anticipation
  • One Exercise Session Can Fight Cancer! Latest Study Confirms: These Two Exercise Types Instantly Produce Anti-Cancer Substances That Significantly Inhibit Cancer Cell Growth
  • The Science of Sleep: Optimal Bedtime and Its Impact on Health
  • About us
  • Contact us
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease Antibiotics breast cancer cardiovascular health clinical trial clinical trials Dementia depression diabetes diet epidemiology exercise FDA FDA approval health healthcare HIV Hypertension immunity immunotherapy longevity men's health mental health nutrition obesity older adults Pediatrics phase 3 trial Physical Activity Pregnancy prevention public health randomized trial semaglutide sexual health sleep stroke targeted therapy treatment type 2 diabetes Vaccine weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top